Unlock the full potential of your medical coding capabilities with the CPT® Advanced Coding Pack from the American Medical Association (AMA). Designed for professional medical coders, auditors, and billers like you, this comprehensive suite of resources provides everything you need to navigate the complexities of the CPT code set with confidence and precision.
Advanced Coding Pack includes:
CPT Assistant - Newsletter with official education and guidance
CPT Knowledge Base - Commonly asked coding questions answered by the experts
CPT Vignettes - Comprehensive clinical examples.
Add to your Find-A-Code subscription for $300 / person
Learn More and Subscribe
1C61.3 HIV disease clinical stage 4 associated with malaria International Classification of Diseases for Mortality and Morbidity Statistics, 11th Revision, v2024-01 code elsewhere sections/codes in this section (1C61.3-1C61.3) postcoordination Add Stem and/or Extension codes to form a cluster code which adds detail to the condition.
Has manifestation - multiple selections are allowed [select] MG30 Chronic pain – MG30.0 Chronic primary pain – MG30.1 Chronic cancer related pain – MG30.2 Chronic postsurgical or post traumatic pain – MG30.3 Chronic secondary musculoskeletal pain – MG30.4 Chronic secondary visceral pain – MG30.5 Chronic neuropathic pain – MG30.6 Chronic secondary headache or orofacial pain – MG30.Y Other specified chronic pain – MG30.Z Chronic pain, unspecified –– MG30.00 Chronic primary visceral pain –– MG30.01 Chronic widespread pain –– MG30.02 Chronic primary musculoskeletal pain –– MG30.03 Chronic primary headache or orofacial pain –– MG30.04 Complex regional pain syndrome –– MG30.0Y Other specified chronic primary pain –– MG30.0Z Chronic primary pain, unspecified –– MG30.10 Chronic cancer pain –– MG30.11 Chronic post cancer treatment pain –– MG30.1Y Other specified chronic cancer related pain –– MG30.1Z Chronic cancer related pain, unspecified –– MG30.20 Chronic post traumatic pain –– MG30.21 Chronic postsurgical pain –– MG30.2Y Other specified chronic postsurgical or post traumatic pain –– MG30.2Z Chronic postsurgical or post traumatic pain, unspecified –– MG30.30 Chronic secondary musculoskeletal pain from persistent inflammation –– MG30.31 Chronic secondary musculoskeletal pain associated with structural changes –– MG30.32 Chronic secondary musculoskeletal pain due to disease of the nervous system –– MG30.3Y Other specified chronic secondary musculoskeletal pain –– MG30.3Z Chronic secondary musculoskeletal pain, unspecified –– MG30.40 Chronic visceral pain from mechanical factors –– MG30.41 Chronic visceral pain from vascular mechanisms –– MG30.42 Chronic visceral pain from persistent inflammation –– MG30.4Y Other specified chronic secondary visceral pain –– MG30.4Z Chronic secondary visceral pain, unspecified –– MG30.50 Chronic central neuropathic pain –– MG30.51 Chronic peripheral neuropathic pain –– MG30.5Y Other specified chronic neuropathic pain –– MG30.5Z Chronic neuropathic pain, unspecified –– MG30.61 Chronic dental pain –– MG30.62 Chronic neuropathic orofacial pain –– MG30.63 Headache or orofacial pain associated with chronic secondary temporomandibular disorders –– MG30.64 Chronic headache or orofacial pain associated with disorders of homoeostasis or their nonpharmacological treatment –– MG30.65 Chronic headache or orofacial pain associated with cranial or cervical vascular disorder –– MG30.66 Chronic headache or orofacial pain associated with non-vascular intracranial disorder –– MG30.67 Chronic headache associated with a substance or its withdrawal –– MG30.6Y Other specified chronic secondary headache or orofacial pain –– MG30.6Z Chronic secondary headache or orofacial pain, unspecified Associated with - multiple selections are allowed [select] 1A32 Cryptosporidiosis 1A33 Cystoisosporiasis – 1A33.0 Cystoisosporiasis of small intestine – 1A33.1 Cystoisosporiasis of colon – 1A33.Y Other specified cystoisosporiasis – 1A33.Z Cystoisosporiasis, unspecified 1B21 Infections due to non-tuberculous mycobacteria 1B21.0 Pulmonary infection due to non-tuberculous mycobacterium 1B21.1 Non-tuberculous mycobacterial lymphadenitis 1B21.2 Cutaneous non-tuberculous mycobacterial infection 1B21.3 Disseminated non-tuberculous mycobacterial infection 1B21.4 Gastrointestinal non-tuberculous mycobacterial infection 1B21.Y Non-tuberculous mycobacterial infection of other specified site 1B21.Z Non-tuberculous mycobacterial infection of unspecified site – 1B21.20 Mycobacterium ulcerans infection – 1B21.2Y Cutaneous infection due to other specified non-tuberculous mycobacteria – 1B21.2Z Cutaneous infection due to unspecified non-tuberculous mycobacteria 1D82 Cytomegaloviral disease 1D82.0 Cytomegaloviral hepatitis 1D82.1 Cytomegaloviral pancreatitis 1D82.Y Other specified cytomegaloviral disease 1D82.Z Cytomegaloviral disease, unspecified 1F00 Herpes simplex infections 1F00.0 Herpes simplex infection of skin or mucous membrane 1F00.1 Herpes simplex infection of the eye 1F00.2 Herpes simplex infection of central nervous system 1F00.3 Disseminated herpes simplex infection 1F00.Y Other specified herpes simplex infections 1F00.Z Herpes simplex infections, unspecified – 1F00.00 Herpes simplex infection of skin – 1F00.01 Herpes simplex labialis – 1F00.02 Herpes simplex gingivostomatitis – 1F00.03 Disseminated cutaneous herpes simplex infection complicating other skin diseases – 1F00.0Y Other specified herpes simplex infection of skin or mucous membrane – 1F00.10 Herpes simplex keratitis – 1F00.11 Herpes simplex infection of eyelid – 1F00.1Y Other specified herpes simplex infection of the eye – 1F00.1Z Herpes simplex infection of the eye, unspecified – 1F00.20 Herpes simplex meningitis – 1F00.21 Encephalitis due to herpes simplex virus – 1F00.2Y Other specified herpes simplex infection of central nervous system 1F23.2 Candidosis of gastrointestinal tract 1F27.2 Disseminated cryptococcosis 1F40 Malaria due to Plasmodium falciparum – 1F40.0 Plasmodium falciparum malaria with cerebral complications – 1F40.Y Other severe and complicated Plasmodium falciparum malaria – 1F40.Z Malaria due to Plasmodium falciparum, unspecified 1F41 Malaria due to Plasmodium vivax – 1F41.0 Plasmodium vivax malaria with rupture of spleen – 1F41.Y Malaria due to Plasmodium vivax with other complications – 1F41.Z Plasmodium vivax malaria without complication 1F42 Malaria due to Plasmodium malariae – 1F42.0 Plasmodium malariae malaria with nephropathy – 1F42.Y Malaria due to Plasmodium malariae with other complications – 1F42.Z Plasmodium malariae malaria without complication 1F43 Malaria due to Plasmodium ovale 1F44 Other parasitologically confirmed malaria 1F57 Toxoplasmosis – 1F57.0 Hepatitis due to Toxoplasma gondii – 1F57.1 Meningoencephalitis due to Toxoplasma gondii – 1F57.2 Pulmonary toxoplasmosis due to Toxoplasma gondii – 1F57.3 Eye disease due to Toxoplasma gondii – 1F57.Y Other specified toxoplasmosis – 1F57.Z Toxoplasmosis, unspecified 2A20 Non mast cell myeloproliferative neoplasms – 2A20.0 Chronic myelogenous leukaemia, BCR-ABL1-positive – 2A20.1 Chronic neutrophilic leukaemia – 2A20.2 Primary myelofibrosis – 2A20.3 Chronic eosinophilic leukaemia, not elsewhere classified – 2A20.4 Polycythaemia vera – 2A20.5 Non mast cell myeloproliferative neoplasm, unclassifiable – 2A20.Y Other specified non mast cell myeloproliferative neoplasms – 2A20.Z Non mast cell myeloproliferative neoplasms, unspecified –– 2A20.00 Chronic myelogenous leukaemia with blast crisis –– 2A20.01 Chronic myelogenous leukaemia, Philadelphia chromosome (Ph1) positive –– 2A20.02 Chronic myelogenous leukaemia, t(9:22)(q34; q11) –– 2A20.03 Naegeli-type monocytic leukaemia –– 2A20.0Y Other specified chronic myelogenous leukaemia, BCR-ABL1-positive –– 2A20.0Z Chronic myelogenous leukaemia, BCR-ABL1-positive, unspecified 2A21 Mastocytosis – 2A21.0 Systemic mastocytosis – 2A21.1 Cutaneous mastocytosis – 2A21.2 Mast cell sarcoma – 2A21.3 Extracutaneous mastocytoma – 2A21.Y Other specified mastocytosis – 2A21.Z Mastocytosis, unspecified –– 2A21.00 Mast cell leukaemia –– 2A21.0Y Other specified systemic mastocytosis –– 2A21.0Z Systemic mastocytosis, unspecified –– 2A21.10 Urticaria pigmentosa –– 2A21.1Y Other specified cutaneous mastocytosis –– 2A21.1Z Cutaneous mastocytosis, unspecified 2A22 Other and unspecified myeloproliferative neoplasms 2A30 Refractory anaemia 2A31 Refractory neutropaenia 2A32 Refractory thrombocytopenia 2A33 Refractory anaemia with ring sideroblasts 2A34 Refractory cytopenia with multi-lineage dysplasia 2A35 Refractory anaemia with excess of blasts 2A36 Myelodysplastic syndrome with isolated del(5q) 2A37 Myelodysplastic syndrome, unclassifiable 2A38 Refractory cytopenia of childhood 2A3Y Other specified myelodysplastic syndromes 2A3Z Myelodysplastic syndromes, unspecified 2A40 Chronic myelomonocytic leukaemia 2A41 Atypical chronic myeloid leukaemia, BCR-ABL1-negative 2A42 Juvenile myelomonocytic leukaemia – 2A42.0 Juvenile myelomonocytic leukaemia in complete remission – 2A42.Y Other specified juvenile myelomonocytic leukaemia – 2A42.Z Juvenile myelomonocytic leukaemia, unspecified 2A43 Refractory anaemia with ring sideroblasts associated with marked thrombocytosis 2A44 Myeloproliferative and myelodysplastic disease, unclassifiable 2A4Y Other specified myelodysplastic and myeloproliferative neoplasms 2A4Z Myelodysplastic and myeloproliferative neoplasms, unspecified 2A50 Myeloid/lymphoid neoplasm associated with PDGFRA rearrangement 2A51 Myeloid neoplasm associated with PDGFRB rearrangement 2A52 Myeloid or lymphoid neoplasms with FGFR1 abnormalities 2A5Z Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1, unspecified 2A60 Acute myeloid leukaemias and related precursor neoplasms 2A60.0 Acute myeloid leukaemia with recurrent genetic abnormalities 2A60.1 Acute myeloid leukaemia with myelodysplasia-related changes 2A60.2 Therapy-related myeloid neoplasms 2A60.3 Acute myeloid leukaemia, not elsewhere classified by criteria of other types 2A60.4 Myeloid proliferation associated with Down syndrome 2A60.5 Blastic plasmacytoid dendritic cell neoplasm 2A60.Y Other specified acute myeloid leukaemias and related precursor neoplasms 2A60.Z Acute myeloid leukaemias and related precursor neoplasms, unspecified – 2A60.20 Therapy related acute myeloid leukaemia or myelodysplastic syndrome – 2A60.2Y Other specified therapy-related myeloid neoplasms – 2A60.2Z Therapy-related myeloid neoplasms, unspecified – 2A60.30 Acute myeloid leukaemia with minimal differentiation – 2A60.31 Acute myeloid leukaemia without maturation – 2A60.32 Acute myeloid leukaemia with maturation – 2A60.33 Acute myelomonocytic leukaemia – 2A60.34 Acute monoblastic or monocytic leukaemia – 2A60.35 Acute erythroid leukaemia – 2A60.36 Acute megakaryoblastic leukaemia – 2A60.37 Acute basophilic leukaemia – 2A60.38 Acute panmyelosis with myelofibrosis – 2A60.39 Myeloid sarcoma – 2A60.3Y Other specified acute myeloid leukaemia, not elsewhere classified by criteria of other types – 2A60.3Z Acute myeloid leukaemia, unspecified – 2A60.40 Transient abnormal myelopoiesis – 2A60.41 Myeloid leukaemia associated with Down syndrome – 2A60.4Y Other specified myeloid proliferation associated with Down syndrome – 2A60.4Z Myeloid proliferation associated with Down syndrome, unspecified 2A61 Acute leukaemias of ambiguous lineage 2A70 Precursor B-lymphoblastic neoplasms – 2A70.0 B lymphoblastic leukaemia or lymphoma, not elsewhere classified – 2A70.1 B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1 – 2A70.Y Other B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities 2A71 Precursor T-lymphoblastic neoplasms 2A7Z Precursor lymphoid neoplasms, unspecified 2A80 Follicular lymphoma – 2A80.0 Follicular lymphoma grade 1 – 2A80.1 Follicular lymphoma grade 2 – 2A80.2 Follicular lymphoma grade 3 – 2A80.3 Primary cutaneous follicle centre lymphoma – 2A80.4 Paediatric type follicular lymphoma – 2A80.5 Follicular lymphoma in situ – 2A80.6 Follicular lymphoma of small intestine – 2A80.Y Other specified follicular lymphoma – 2A80.Z Follicular lymphoma, unspecified 2A81 Diffuse large B-cell lymphomas – 2A81.0 Primary mediastinal large B-cell lymphoma – 2A81.1 Intravascular large B-cell lymphoma – 2A81.2 Plasmablastic lymphoma – 2A81.3 Lymphomatoid granulomatosis – 2A81.4 T-cell/histiocyte rich large B-cell lymphoma – 2A81.5 Primary diffuse large B-cell lymphoma of central nervous system – 2A81.6 Epstein-Barr Virus-positive diffuse large B-cell lymphoma of the elderly – 2A81.7 Diffuse large B-cell lymphoma associated with chronic inflammation – 2A81.8 ALK-positive large B-cell lymphoma – 2A81.9 Primary effusion lymphoma – 2A81.A Primary cutaneous diffuse large B-cell lymphoma, leg type – 2A81.Y Other specified diffuse large B-cell lymphomas – 2A81.Z Diffuse large B-cell lymphoma, not otherwise specified 2A82 Mature B-cell neoplasm with leukaemic behaviour – 2A82.0 Chronic lymphocytic leukaemia or small lymphocytic lymphoma – 2A82.1 B-cell prolymphocytic leukaemia – 2A82.2 Hairy-cell leukaemia – 2A82.3 Splenic B-cell lymphoma or leukaemia, unclassifiable – 2A82.Y Other specified mature B-cell neoplasm with leukaemic behaviour – 2A82.Z Mature B-cell neoplasm with leukaemic behaviour, unspecified –– 2A82.00 Chronic lymphocytic leukaemia of B-cell type –– 2A82.0Y Other specified chronic lymphocytic leukaemia or small lymphocytic lymphoma –– 2A82.0Z Chronic lymphocytic leukaemia or small lymphocytic lymphoma, unspecified –– 2A82.10 B-cell prolymphocytic leukaemia in complete remission –– 2A82.1Y Other specified b-cell prolymphocytic leukaemia –– 2A82.1Z B-cell prolymphocytic leukaemia, unspecified 2A83 Plasma cell neoplasms – 2A83.0 Monoclonal gammopathy of undetermined significance – 2A83.1 Plasma cell myeloma – 2A83.2 Solitary plasmacytoma – 2A83.3 Extraosseous plasmacytoma – 2A83.4 Plasma cell leukaemia – 2A83.5 Monoclonal immunoglobulin deposition disease – 2A83.Y Other specified multiple myeloma and plasma cell neoplasms – 2A83.Z Plasma cell neoplasm, unspecified –– 2A83.50 Heavy chain deposition disease –– 2A83.51 Light and heavy chain deposition disease –– 2A83.52 Light chain deposition disease 2A84 Heavy chain diseases or malignant immunoproliferative diseases – 2A84.0 Alpha heavy chain disease – 2A84.1 Gamma heavy chain disease – 2A84.2 Mu heavy chain disease – 2A84.Y Other specified malignant immunoproliferative diseases – 2A84.Z Heavy chain diseases, unspecified 2A85 Other specified mature B-cell neoplasms or lymphoma – 2A85.0 Nodal marginal zone lymphoma – 2A85.1 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of stomach – 2A85.2 Extranodal marginal zone B-cell lymphoma, primary site skin – 2A85.3 Extranodal marginal zone B-cell lymphoma, primary site excluding stomach or skin – 2A85.4 Lymphoplasmacytic lymphoma – 2A85.5 Mantle cell lymphoma – 2A85.6 Burkitt lymphoma including Burkitt leukaemia – 2A85.Y Further specified mature B-cell neoplasms or lymphoma 2A86 B-cell lymphoma, mixed features – 2A86.0 Malignant lymphoma of B cell type, not elsewhere classified – 2A86.1 B-cell lymphoma unclassifiable with features intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma – 2A86.2 B-cell lymphoma unclassifiable with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma – 2A86.Y Other specified B-cell lymphoma, mixed features – 2A86.Z B-cell lymphoma, mixed features, unspecified 2A8Z Mature B-cell neoplasms, unspecified 2A90 Mature T-cell lymphoma, specified types, nodal or systemic – 2A90.0 T-cell prolymphocytic leukaemia – 2A90.1 T-cell large granular lymphocytic leukaemia – 2A90.2 Chronic lymphoproliferative disorders of NK-cells – 2A90.3 Aggressive NK cell leukaemia – 2A90.4 Systemic Epstein-Barr Virus-positive T-cell lymphoma of childhood – 2A90.5 Adult T-cell lymphoma or leukaemia, human T-cell lymphotropic virus type 1-associated – 2A90.6 Extranodal NK/T-cell lymphoma, nasal type – 2A90.7 Enteropathy associated T-cell lymphoma – 2A90.8 Hepatosplenic T-cell lymphoma – 2A90.9 Angioimmunoblastic T-cell lymphoma – 2A90.A Anaplastic large cell lymphoma, ALK-positive – 2A90.B Anaplastic large cell lymphoma, ALK-negative – 2A90.C Peripheral T-cell lymphoma, not otherwise specified – 2B00 Subcutaneous panniculitis-like T-cell lymphoma – 2B01 Mycosis fungoides – 2B02 Sézary syndrome – 2B03 Primary cutaneous CD30-positive T-cell lymphoproliferative disorders –– 2B03.0 Primary cutaneous CD30-positive anaplastic large cell lymphoma –– 2B03.1 Lymphomatoid papulosis – 2B0Y Other specified primary cutaneous mature T-cell or NK-cell lymphomas and lymphoproliferative disorders – 2B0Z Primary cutaneous T-cell lymphoma of undetermined or unspecified type 2B2Y Other specified mature T-cell or NK-cell neoplasms 2B2Z Mature T-cell or NK-cell neoplasms, unspecified 2B30 Hodgkin lymphoma 2B30.0 Nodular lymphocyte predominant Hodgkin lymphoma 2B30.1 Classical Hodgkin lymphoma 2B30.Z Hodgkin lymphoma, unspecified – 2B30.10 Nodular sclerosis classical Hodgkin lymphoma – 2B30.11 Lymphocyte-rich classical Hodgkin lymphoma – 2B30.12 Mixed cellularity classical Hodgkin lymphoma – 2B30.13 Lymphocyte depleted classical Hodgkin lymphoma – 2B30.1Z Classical Hodgkin lymphoma, unspecified 2B31 Histiocytic or dendritic cell neoplasms 2B31.0 Juvenile xanthogranuloma 2B31.1 Histiocytic sarcoma 2B31.2 Langerhans cell histiocytosis 2B31.3 Langerhans cell sarcoma 2B31.4 Interdigitating dendritic cell sarcoma 2B31.5 Follicular dendritic cell sarcoma 2B31.6 Indeterminate cell histiocytosis 2B31.7 Fibroblastic reticular cell tumour 2B31.Y Other specified histiocytic or dendritic cell neoplasms 2B31.Z Histiocytic or dendritic cell neoplasms, unspecified – 2B31.20 Langerhans cell histiocytosis involving the skin – 2B31.2Y Other specified Langerhans cell histiocytosis – 2B31.2Z Langerhans cell histiocytosis, unspecified 2B32 Immunodeficiency-associated lymphoproliferative disorders 2B32.0 Post-transplant lymphoproliferative disorder, early lesion 2B32.1 Reactive plasmacytic hyperplasia 2B32.2 Post-transplant lymphoproliferative disorder, Infectious mononucleosis-like 2B32.3 Polymorphic post-transplant lymphoproliferative disorder 2B32.Y Other specified immunodeficiency-associated lymphoproliferative disorders 2B32.Z Immunodeficiency-associated lymphoproliferative disorders, unspecified 2B33 Malignant haematopoietic neoplasms without further specification 2B33.0 Acute leukaemia, not elsewhere classified 2B33.1 Myeloid leukaemia 2B33.2 Chronic myeloid leukaemia, not elsewhere classified 2B33.3 Lymphoid leukaemia, not elsewhere classified 2B33.4 Leukaemia, unspecified 2B33.5 Malignant lymphoma, not elsewhere classified 2B33.Y Other malignant haematopoietic neoplasms without further specification 2B3Z Neoplasms of haematopoietic or lymphoid tissues, unspecified – 2B57 Kaposi sarcoma, primary site –– 2B57.0 Kaposi sarcoma of lung –– 2B57.1 Kaposi sarcoma of skin –– 2B57.2 Kaposi sarcoma of gastrointestinal sites –– 2B57.Y Kaposi sarcoma of other specified primary sites –– 2B57.Z Kaposi sarcoma of unspecified primary site – 6D85.3 Dementia due to human immunodeficiency virus – 8A45.02 Progressive multifocal leukoencephalopathy – CA40.20 Pneumonia due to pneumocystis – MG53.0 Antiretroviral therapy resistant Human immunodeficiency virus
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Quick, Current, Complete - www.findacode.com